MACUGEN 0.3mg injectible solution medication leaflet

S01LA03 pegaptanib sodium • Sensory organs | Ocular vascular disorder agents | Antineovascularisation agents

Pegaptanib sodium is a medication used in the treatment of neovascular age-related macular degeneration (AMD). It works by inhibiting vascular endothelial growth factor (VEGF), reducing the formation of abnormal blood vessels in the retina.

The medication is administered via intravitreal injection, as directed by a doctor, usually once every six weeks. It is important for patients to attend scheduled treatments and inform the doctor of any unusual symptoms.

Patients should be aware of potential side effects, such as eye pain, inflammation, or infections. It is important to inform the doctor of any unusual symptoms.

Common side effects include eye pain, inflammation, and a foreign body sensation in the eye. In rare cases, severe reactions such as endophthalmitis or retinal detachment may occur. Patients should be informed of these risks before use.

General data about MACUGEN 0.3mg INJECTIBLE SOLUTION

Substance: pegaptanib sodium

Date of last drug list: 01-07-2013

Commercial code: W43716001

Concentration: 0.3mg

Pharmaceutical form: injectible solution

Quantity: 1

Product type: original

Prescription restrictions: S - Medicines prescription reserved for use in certain specialized fields.